The Board of Directors of Peptonic Medical AB (the “Company”) hereby announces that the Company’s issue of shares with preferential rights of approximately SEK 25.4 million, which was decided and announced on November 19, 2020 and for which the subscription period ended on December 15, 2020 (the “Rights Issue”), has been completed. In the Rights Issue, 21,775,059 shares were subscribed for, corresponding to approximately 94% of the Rights Issue, with the support of subscription rights. In addition, 40,642,271 shares were subscribed for, corresponding to approximately 175% of the Rights Issue, without the support of subscription rights. In total, the Rights Issue has been subscribed for approximately 268%. The company will receive approximately SEK 25.4 million through the Rights Issue before deductions for issue costs.
The outcome of the Rights Issue
The rights issue comprised a maximum of 23,273,087 shares in the Company and the subscription period ran during the period 1–15 December 2020. The subscription price was SEK 1.09 per share. The Rights Issue was subscribed for at a total of approximately 268%, of which 93.6% with the support of subscription rights and 174.6% without the support of subscription rights. The Company will receive approximately SEK 25.4 million through the Rights Issue before deductions for issue costs, which amounted to approximately SEK 0.7 million (2.8%).
“We are extremely proud and please that the interest in Peptonic is so great. The outcome of the issue was as good as we could have wished for. The cash now injected in the Company means that we can continue to invest in both new launches and in broadening our portfolio with several products that improve women’s health and well-being, ”says Johan Inborr, CEO of Peptonic.
Allotment of shares subscribed for without the support of subscription rights takes place in accordance with the principles stated in the Information Memorandum prepared in connection with the Rights Issue and published by the Company on 19 November 2020. Notice of allotment is given by settlement note sent by post to each subscriber. The settlement note is expected to be distributed around December 21, 2020. Allotted shares must be paid in accordance with the instructions on the settlement note. Only those who receive an allotment will be notified.
Shares and share capital
Through the Rights Issue, the Company’s share capital will increase by SEK 2,327,308.70, from SEK 16,291,161.30 to SEK 18,618,470.00 and the number of shares will increase by 23,273,087 shares, from 162,911,613 shares to 186,184,700. shares. The dilution effect for shareholders who have not participated in the Rights Issue thus amounts to approximately 12.5%.
Trade with BTA
Trading in paid subscribed shares (“BTA”) on the Spotlight Stock Market continues under the short name “PMED BTA” (ISIN code: SE0015222377) until the Rights Issue has been registered with the Swedish Companies Registration Office and BTA has been converted into shares, which is expected to take place around week 5 , 2021.
Eminova Fondkommission AB acts as an issue institution for the Company in connection with the Rights Issue.
The information in this press release neither contains nor constitutes an offer to acquire, subscribe for or otherwise trade in shares or other securities in the Company. No action has been taken and no action will be taken to allow an offer to the public in any jurisdiction other than Sweden. Invitation to the persons concerned to subscribe for shares in the Company has only taken place through the Information Memorandum published on 26 November 2020.
The information in this press release may not be published, published or distributed, directly or indirectly, within or to the United States, Australia, Japan, Canada or any other jurisdiction where such action would be illegal, subject to legal restrictions or require action other than that resulting from Swedish law. Measures in violation of these instructions may constitute a violation of applicable securities laws. No shares or other securities of the Company have been registered, and no shares or other securities will be registered, under the then-current United States Securities Act of 1933 (the Securities Act) or the securities laws of any state or other jurisdiction in the United States and may not offered, sold or otherwise transferred, directly or indirectly, in or to the United States, except in accordance with an applicable exemption from, or in a transaction not covered by, the Securities Act registration requirements and in accordance with the securities laws of the relevant state; or other jurisdiction in the United States.
Within the European Economic Area (“EEA”), no offer of shares or other securities is made available to the public in any country other than Sweden. In other Member States of the European Union (“EU”), such an offer may only be made in accordance with the exceptions in the Prospectus Regulation (EU) 2017/1129 (the “Prospectus Regulation”). In other countries in the EEA that have implemented the Prospectus Regulation in national legislation, such an offer can only be made in accordance with exceptions in the Prospectus Regulation and in accordance with any relevant implementation measure. In other countries in the EEA that have not implemented the Prospectus Regulation in national law, such an offer can only be made in accordance with the applicable exception in national law.
Not for publication, release or distribution, DIRECTLY OR INDIRECTLY, IN OR FOR AUSTRALIA, Hong Kong, Japan, Canada, Singapore, SOUTH AFRICA, NEW ZEALAND OR OTHER jurisdiction where the announcement, publication or distribution RELEASE WOULD BE ILLEGAL OR REQUIRE REGISTRATION OR OTHER ACTION. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER FOR, OR AN INVITATION TO, ACQUIRE OR SUBSCRIBE ANY SECURITIES IN PEPTONIC MEDICAL AB IN ANY JURISDICTION.
For more information, please contact;
Johan Inborr, CEO
Mobile: +46 708 853 893
This information is information that Peptonic Medical AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 17th December, 2020.
About Peptonic Medical
Peptonic Medical is an innovative Swedish medical development company. Its vision is to offer safe and effective treatments and relief for women specific diseases and medical conditions.
VagiVital® is a registered trademark of Peptonic Medical. The product is hormone free and is being commercialised for the non-prescription use for the treatment of vaginal atrophy (VA) and vaginal dryness. The pipeline of Peptonic Medical also includes Vagitocin®, which is an oxytocin-based vaginal gel for the treatment of VA. This product candidate is in clinical development phase 2. The development of Vagitocin® is on hold pending additional data on i.a. the mechanism of action.
Since July 2014, the Peptonic Medical share has been traded on the Spotlight Stock Exchange (www.spotlightstockmarket.se, ticker: PMED) in Stockholm, Sweden.
For more information: www.peptonicmedical.com